Stem Cell Research (May 2021)
Generation of an ELTD1 knockout human embryonic stem cell line by the iCRISPR/Cas9 system
- Qian Luo,
- Cong Wei,
- Yan Long,
- Meng Zhang,
- Wei Shan,
- Honghu Li,
- Shuyang Cai,
- Yulin Xu,
- Pengxu Qian,
- He Huang
Affiliations
- Qian Luo
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China
- Cong Wei
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China
- Yan Long
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China
- Meng Zhang
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China
- Wei Shan
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China
- Honghu Li
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China
- Shuyang Cai
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China
- Yulin Xu
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China
- Pengxu Qian
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China; Center of Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Hangzhou 310012, PR China; Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Corresponding authors at: BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China.
- He Huang
- BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Institute of Hematology, Zhejiang University, Hangzhou 310012, Zhejiang, PR China; Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou 310012, Zhejiang, PR China; Zhejiang Laboratory for Systems & Precision Medicine, Zhejiang University Medical Center, Hangzhou 310012, Zhejiang, PR China; Center of Stem Cell and Regenerative Medicine, School of Medicine, Zhejiang University, Hangzhou 310012, PR China; Corresponding authors at: BoneMarrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310012, Zhejiang, PR China.
- Journal volume & issue
-
Vol. 53
p. 102350
Abstract
Human ELTD1 (Epidermal growth factor, latrophilin and seven-transmembrane domain-containing 1), an orphan G-protein-coupled receptor (GPCR) belonging to the adhesion GPCR family, has been reported as a novel regulator of angiogenesis and a potential anti-cancer therapeutic target. However, little is known about the function of ELTD1, especially its undiscovered ligands. In this experiment, an ELTD1 homozygous knockout human embryonic stem cell line, FAHZUe001-A, was generated by the iCRISPR/Cas9 system to achieve a deeper understanding of ELTD1. The FAHZUe001-A was confirmed with normal karyotype, typical undifferentiated morphology, pluripotency and trilineage differentiation potential in vitro.
